Meeting
2018 Genitourinary Cancers Symposium
Opinions on the role of brachytherapy boost in management of high-risk prostate cancer: A survey of North American genitourinary expert radiation oncologists.
Authors
Shearwood McClelland III
Oregon Health and Science University, Portland, OR
Shearwood McClelland III, Kiri A Sandler , Catherine Degnin , Yiyi Chen , Timur Mitin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 373)
DOI
10.1200/JCO.2018.36.6_suppl.373
Abstract #
373
Poster Bd #
E20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Results of a multicenter, randomized, phase 3 trial of trimodality therapy with I-125 brachytherapy, external beam radiation therapy, and long- versus short-term androgen deprivation therapy for localized high-risk prostate cancer (TRIP/TRIGU0907).
First Author: Atsunori Yorozu
Poster
2019 Genitourinary Cancers Symposium
External beam radiation therapy and brachytherapy boost versus radical prostatectomy and adjuvant radiation therapy for high-risk prostate cancer.
First Author: Vinayak Muralidhar
Poster
2016 Genitourinary Cancers Symposium
Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable intermediate- and high-risk prostate cancer.
First Author: Michael A Dyer
Poster
2016 Genitourinary Cancers Symposium
Comparisons of outcomes for patients with high-risk prostate cancer treated with brachytherapy, external beam radiation, or radical prostatectomy.
First Author: Jay P. Ciezki